LOGO
LOGO

Indivior Lifts 2025 Outlook On Strong Q2 Momentum

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

Indivior PLC (INDV) has raised its outlook for full-year 2025 to reflect better-than-expected net revenue performance in the first half of the year.

This global pharmaceutical company is focused on developing medicines to treat addiction. Its marketed products include Sublocade, Suboxone, and Opvee, which are distributed in over 30 countries worldwide.

-- Sublocade, a once-monthly injectable partial opioid agonist formulation for the treatment of opioid use disorder.
-- Suboxone is a sublingual film indicated for the treatment of opioid dependence.
-- Opvee nasal spray is an opioid antagonist indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.